---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-163400"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:19:14.864396+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Rein Therapeutics stockholders elect director Fairey, approve say-on-pay

## Summary
- William C. Fairey elected as Class II director for three-year term expiring 2028; 7,661,847 for, 1,621,599 withheld.
- Advisory vote on named executive officer compensation approved: 8,325,803 for, 146,938 against, 810,705 abstain.
- Meeting held July 23, 2025, after being adjourned from June 24, 2025; no broker non-votes recorded.

## SEC filing metadata
- accession: 0001193125-25-163400
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312525163400/0001193125-25-163400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312525163400/d931384d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-163400
- JSON: https://secwatch.observer/filing/0001193125-25-163400.json
- Plain text: https://secwatch.observer/filing/0001193125-25-163400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.